Overview

T-Cell Acute Lymphoblastic Leukemia Market is estimated to value over USD 330 million by 2027 end and register a CAGR of over 6.3% during the forecast period 2020 to 2027.

The growth of the market is steered by a rise in the occurrence of t-cell acute lymphoblastic leukemia. The t-cell acute lymphoblastic leukemia market growth is predicted to take place at a meteoric pace over the forecast period. This can be credited to a strong product pipeline and an increase in the number of cancer awareness programs.

As per the American Society of Clinical Oncology, t-cell acute lymphoblastic leukemia held over 17% of all acute lymphoblastic leukemia. As per a recent survey, nearly 5,900 cases of (ALL) were reported in the U.S in 2017. Every 4 in 10 patients were adults. Furthermore, an increase in the overall expenditure assigned to health care and ever-increasing clinical trials are predicted to stimulate market growth.

The chemotherapy treatments held a major t-cell acute lymphoblastic leukemia market share with respect to revenue in 2018. This segment is predicted to inflate at a substantial growth rate over the forecast period owing to its high rate of prescription, easy availability and a wide products range.

The Asia-Pacific region is also projected to proliferate at a high CAGR over the forecast period due to multiple factors, for instance, high incomplete clinical necessities, huge patient population and the growing awareness about early diagnosis in emerging nations like India and China.

Key market players included in the T-cell acute lymphoblastic leukemia industry are Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma Inc., Celgene Corp.

T-Cell Acute Lymphoblastic Leukemia Market Segmentation:

By Treatment

• Chemotherapy
• Radiation Therapy
• Bone Marrow Transplant
• Targeted Therapy
• Immunotherapy

By End User

• Hospitals
• Clinics
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the t-cell acute lymphoblastic leukemia market by treatment, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
• To forecast and evaluate micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
• To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

Table of Contents

1 Introduction 

1.1 Objectives of the Study 

1.2 Market Definition 

        1.2.1 Markets Covered

        1.2.2 Years Considered for the Study

1.3 Currency 

1.4 Limitations 

1.5 Stakeholders 

2 Research Methodology 

2.1 Research Approach 

2.2 Research Data 

        2.2.1 Secondary Sources

                 2.2.1.1 Key Data From Secondary Sources

        2.2.2 Primary Sources

                 2.2.2.1 Key Data From Primary Sources

                 2.2.2.2 Breakdown of Primary Interviews

2.3 Market Size Estimation 

2.4 Market Breakdown and Data Triangulation 

2.5 Research Assumptions 

3 Executive Summary 

4 Market Overview

     4.1. Introduction

     4.2. Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2017–2027

     4.3. Global T-cell Acute Lymphoblastic Leukemia Market Outlook

     4.4. Key Industry Developments

     4.5. T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis

     4.6. Nelarabine: Clinical Trial

     4.7. Acute Lymphocytic Leukemia New Cases, 2019

     4.8. Reimbursement Scenario for Cancer Treatment

     4.9. Regulatory Guidelines for Therapeutics

5. Market Dynamics

     5.1. Drivers and Restraints Snapshot Analysis

     5.2. Drivers

     5.3. Restraints

     5.4. Opportunities

     5.5. Key Trends

6. Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment

     6.1. Introduction

     6.2. Global T-cell Acute Lymphoblastic Leukemia Market Value Share, by Treatment

     6.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment

            6.3.1. Chemotherapy

            6.3.2. Radiation Therapy

            6.3.3. Bone Marrow Transplant

            6.3.4. Targeted Therapy

            6.3.4. Immunotherapy

7. Global T-cell Acute Lymphoblastic Leukemia Market, by End-user

     7.1. Key Findings

     7.2. Introduction

     7.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user

     7.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by End-user

     7.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by End-user

            7.5.1. Hospitals

            7.5.2. Clinics

            7.5.3. Others

    8. T-cell Acute Lymphoblastic Leukemia Market Analysis, by Region

     8.1. Key Findings

     8.2. Global Market Scenario

     8.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region

     8.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by Region

            8.4.1. North America

            8.4.2. Europe

            8.4.3. Asia Pacific

            8.4.4. Latin America

            8.4.5. Middle East & Africa

9 Competition Landscape

     9.1. Market Player - Competition Matrix (By Tier and Size of companies)

     9.2. Market Share Analysis, by Company (2019)

     9.3. Company Profiles

            9.3.1. Pfizer, Inc.

                     9.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.3.1.2. Financial Overview

                     9.3.1.3. Product Portfolio

                     9.3.1.4. SWOT Analysis

                     9.3.1.5. Strategic Overview

            9.3.2. Novartis AG

                     9.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.3.2.2. Financial Overview

                     9.3.2.3. Product Portfolio

                     9.3.2.4. SWOT Analysis

                     9.3.2.5. Strategic Overview

            9.3.3. F. Hoffmann-La Roche Ltd.

                     9.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.3.3.2. Financial Overview

                     9.3.3.3. Product Portfolio

                     9.3.3.4. SWOT Analysis

                     9.3.3.5. Strategic Overview

            9.3.4. Sanofi

                     9.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.3.4.2. Financial Overview

                     9.3.4.3. Product Portfolio

                     9.3.4.4. SWOT Analysis

                     9.3.4.5. Strategic Overview

            9.3.5. Erytech Pharma Inc.

                     9.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.3.5.2. Financial Overview

                     9.3.5.3. Product Portfolio

                     9.3.5.4. SWOT Analysis

                     9.3.5.5. Strategic Overview

            9.3.6. Celgene Corporation

                     9.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                     9.3.6.2. Financial Overview

                     9.3.6.3. Product Portfolio

                     9.3.6.4. SWOT Analysis

                     9.3.6.5. Strategic Overview

10 Research Finding and Conclusion

11 Research Methodology

12 Research Data Source

Tables

Figures